UNSPSC 51312813: Methiomeprazine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H24N2S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P3V14N8PKW, chemically known as 10h-phenothiazine-10-propanamine, n,n,beta-trimethyl-2-(methylthio)-, monohydrochloride (9ci) but more generally known as methiomeprazine hydrochloride, which bears US NIH Compound Identifier 26429. Most nations, for tariff and trade purposes, schedule methiomeprazine hydrochloride under HS 29343090 and SITC 51578.

As of Q4 2014, METHIOMEPRAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Methiomeprazine hydrochloride bears US NLM identifiers UMLS ID C2825473 and NCI Concept Code C81144. SMILES: CC(CN1C2CCCCC2SC3C1CC(CC3)SC)CN(C)C.CL.

UNSPSC 51312813 Methiomeprazine hydrochloride is a Commodity code that in practice covers pharmaceutical procurement by state and local health agencies, though recent solicitations tagged to this code show minimal alignment with the specific drug name. State and local governments use codes in this family to procure controlled substances, over-the-counter medications, and pharmaceutical products for community health programs, emergency response, and multi-jurisdictional pharmacy benefit administration. Issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple state and local entities. The Seminole County, Florida IFB for naloxone and drug deactivation systems represents direct health commodity procurement; the Texas Health and Human Services Commission RFI on direct-to-manufacturer prescriptions reflects state-level pharmacy benefit strategy; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic pharmaceuticals and OTC products shows how consortial procurement bundles pharmaceutical sourcing across participating states and local jurisdictions.

Recent activity centers on Florida, Texas, and Minnesota, with MMCAP's multi-state cooperative purchasing extending reach to Oregon and other alliance members. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas HHS RFI (HHS0017013, posted April 3, 2026) gathered vendor capability information on direct-to-manufacturer prescription relationships outside traditional pharmacy benefit manager and group purchasing organization channels. The MMCAP RFP (S1070000015802, due March 26, 2026) established contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with pricing weighted at 75 percent, compliance and capability factors at 20 percent, and a July 1, 2026 effective date for awarded vendors. The code shows fragmented demand across isolated county procurement and state-level pharmacy benefit consolidation rather than concentrated recurrence under the specific drug commodity.